Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr S&P Biotech ETF | 13.23% | Hold | 566,000 | $83.00 | $47M | — | — |
| STXS - Stereotaxis | 7.98% | Hold | 13,680,554 | $2.07 | $28M | — | — |
| ASND - Ascendis Pharma A/S | 4.48% | Reduce −4.1% | 130,212 | $122.13 | $16M | −5,500 | +$2M |
| Karuna Therapeutics | 3.99% | Add +149.3% | 72,027 | $196.50 | $14M | +43,141 | +$8M |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.79% | Hold | 102,500 | $131.29 | $13M | — | — |
| Iveric Bio | 3.65% | Add +50.9% | 605,975 | $21.41 | $13M | +204,499 | +$6M |
| XENE - Xenon Pharmaceuticals | 3.51% | Reduce −15.8% | 316,092 | $39.43 | $12M | −59,131 | −$1M |
| Blueprint Medicines | 3.22% | Hold | 261,235 | $43.81 | $11M | — | — |
| RVMD - Revolution Medicines | 3.21% | Reduce −0.4% | 477,785 | $23.82 | $11M | −2,000 | +$2M |
| SNDX - Syndax Pharmaceuticals | 3.20% | Add +25.8% | 447,073 | $25.45 | $11M | +91,586 | +$3M |
| NBIX - Neurocrine Biosciences | 2.46% | Reduce −8.8% | 73,121 | $119.44 | $9M | −7,034 | +$221K |
| IDYA - Ideaya Biosciences | 2.40% | Reduce −13.0% | 468,358 | $18.17 | $9M | −70,203 | +$475K |
| CYTK - Cytokinetics | 2.37% | Hold | 183,995 | $45.82 | $8M | — | — |
| DXCM - Dexcom | 2.15% | Reduce −6.9% | 67,552 | $113.24 | $8M | −5,000 | +$2M |
| Sage Therapeutics | 1.94% | Hold | 180,306 | $38.14 | $7M | — | — |
| EWTX - Edgewise Therapeutics | 1.93% | Reduce −1.8% | 766,843 | $8.94 | $7M | −14,269 | −$830K |
| NRIX - Nurix Therapeutics | 1.75% | Hold | 566,695 | $10.98 | $6M | — | — |
| Adicet Bio | 1.59% | Reduce −32.5% | 631,554 | $8.94 | $6M | −304,212 | −$8M |
| FATE - Fate Therapeutics | 1.57% | Add +2.0% | 550,940 | $10.09 | $6M | +11,000 | −$7M |
| BHVN - Biohaven | 1.54% | Add +156.0% | 393,113 | $13.88 | $5M | +239,549 | +$4M |
| Morphic | 1.47% | Hold | 195,467 | $26.75 | $5M | — | — |
| ALEC - Alector | 1.38% | Hold | 532,438 | $9.23 | $5M | — | — |
| VKTX - Viking Therapeutics | 1.38% | Reduce −5.6% | 521,553 | $9.40 | $5M | −30,847 | +$3M |
| APLSUSD - Apellis Pharmaceuticals | 1.22% | Add +26.5% | 83,446 | $51.71 | $4M | +17,500 | −$189K |
| Merus | 1.18% | Reduce −2.5% | 269,893 | $15.47 | $4M | −7,000 | −$1M |
| Kalvista Pharmaceuticals | 1.17% | Add +141.3% | 616,032 | $6.76 | $4M | +360,719 | +$459K |
| 89BIO | 1.16% | Reduce −50.5% | 324,173 | $12.73 | $4M | −330,689 | +$335K |
| Cardiovascular Systems | 1.10% | Hold | 286,988 | $13.62 | $4M | — | — |
| Dice Therapeutics | 1.09% | Add +57.3% | 123,500 | $31.20 | $4M | +45,000 | +$2M |
| F-Star Therapeutics | 1.03% | Hold | 576,881 | $6.32 | $4M | — | — |
| BCYC - Bicycle Therapeutics | 1.02% | Hold | 122,200 | $29.60 | $4M | — | — |
| Mirati Therapeutics | 0.94% | Add +2.8% | 73,600 | $45.31 | $3M | +2,000 | −$2M |
| AXGN - Axogen | 0.93% | Hold | 332,103 | $9.98 | $3M | — | — |
| ATRC - Atricure | 0.90% | Hold | 72,029 | $44.38 | $3M | — | — |
| CMPX - Compass Therapeutics | 0.85% | Add +220.1% | 602,051 | $5.03 | $3M | +413,957 | +$3M |
| RCUS - Arcus Biosciences | 0.83% | Reduce −20.4% | 142,217 | $20.68 | $3M | −36,500 | −$2M |
| BCRX - Biocryst Pharmaceuticals | 0.81% | New | 251,000 | $11.48 | $3M | +251,000 | +$3M |
| Mediwound | 0.78% | New | 204,082 | $13.49 | $3M | +204,082 | +$3M |
| ARAY - Accuray | 0.72% | Add +29.8% | 1,222,358 | $2.09 | $3M | +280,558 | +$596K |
| IPSC - Century Therapeutics | 0.69% | Hold | 475,367 | $5.13 | $2M | — | — |
| Mersana Therapeutics | 0.68% | Add +9.5% | 413,463 | $5.86 | $2M | +35,700 | −$131K |
| LKFT - Galapagos | 0.66% | Add +23.4% | 52,675 | $44.38 | $2M | +10,000 | +$518K |
| AUTL - Autolus Therapeutics | 0.63% | Add +137.1% | 1,176,150 | $1.90 | $2M | +680,000 | +$1M |
| Neuronetics | 0.61% | Hold | 313,717 | $6.87 | $2M | — | — |
| Vigil Neuroscience | 0.59% | Reduce −22.0% | 168,846 | $12.50 | $2M | −47,549 | +$142K |
| LRMR - Larimar Therapeutics | 0.55% | Reduce −17.7% | 473,136 | $4.13 | $2M | −101,860 | +$114K |
| Iteos Therapeutics | 0.54% | Add +1.0% | 98,560 | $19.53 | $2M | +1,000 | +$66K |
| KURA - Kura Oncology | 0.51% | Reduce −29.8% | 144,784 | $12.41 | $2M | −61,545 | −$1M |
| Keros Therapeutics | 0.45% | Reduce −15.4% | 33,000 | $48.02 | $2M | −6,000 | +$118K |
| ORIC - Oric Pharmaceuticals | 0.44% | Reduce −36.1% | 264,237 | $5.89 | $2M | −149,289 | +$233K |
| Cymabay Therapeutics | 0.30% | Reduce −90.0% | 171,059 | $6.27 | $1M | −1,532,176 | −$5M |
| Syros Pharmaceuticals | 0.27% | Hold | 265,878 | $3.59 | $955K | — | — |
| Genfit S A | 0.24% | Add +5.3% | 197,940 | $4.39 | $869K | +10,000 | +$183K |
| Affimed | 0.24% | Hold | 686,282 | $1.24 | $851K | — | — |
| Mereo Biopharma Group | 0.23% | Hold | 1,096,513 | $0.7500 | $822K | — | — |
| Pardes Biosciences | 0.23% | Hold | 479,386 | $1.69 | $810K | — | — |
| Regulus Therapeutics | 0.21% | Hold | 555,555 | $1.37 | $761K | — | — |
| Karyopharm Therapeutics | 0.18% | New | 192,678 | $3.40 | $655K | +192,678 | +$655K |
| Surface Oncology | 0.18% | Reduce −28.8% | 783,000 | $0.8200 | $642K | −317,000 | −$502K |
| Cincor Pharma | 0.17% | New | 48,000 | $12.29 | $590K | +48,000 | +$590K |
| BWAY - Brainsway | 0.15% | Hold | 220,000 | $2.47 | $543K | — | — |
| Adaptimmune Therapeutics | 0.14% | Hold | 351,064 | $1.46 | $513K | — | — |
| Masimo | 0.13% | Hold | 3,000 | $147.95 | $444K | — | — |
| Kinnate Biopharma | 0.12% | Reduce −9.1% | 71,008 | $6.10 | $433K | −7,066 | −$500K |
| Theseus Pharmaceuticals | 0.11% | Reduce 0.0% | 81,859 | $4.98 | $408K | −40 | −$67K |
| Ikena Oncology | 0.09% | Hold | 122,517 | $2.66 | $326K | — | — |
| Medicenna Therapeutics | 0.09% | Hold | 660,000 | $0.4580 | $302K | — | — |
| INGN - Inogen | 0.08% | Hold | 15,000 | $19.71 | $296K | — | — |
| BMEA - Biomea Fusion | 0.08% | Hold | 34,625 | $8.43 | $292K | — | — |
| Macrogenics | 0.08% | Reduce −60.1% | 39,879 | $6.71 | $268K | −60,121 | −$78K |
| Nextcure | 0.07% | Hold | 187,696 | $1.41 | $265K | — | — |
| SCYXEUR - Scynexis | 0.07% | Reduce −61.6% | 153,269 | $1.56 | $239K | −245,795 | −$719K |
| Spero Therapeutics | 0.06% | Hold | 125,000 | $1.73 | $216K | — | — |
| ACRV - Acrivon Therapeutics | 0.05% | New | 15,648 | $11.52 | $180K | +15,648 | +$180K |
| BDTX — | 0.05% | Reduce −68.9% | 97,500 | $1.80 | $176K | −216,100 | −$355K |
| Holding | 0.05% | Hold | 140,000 | $1.17 | $164K | — | — |
| Compugen | 0.04% | Hold | 205,202 | $0.7157 | $147K | — | — |
| Reunion Neuroscience | 0.01% | Reduce −50.6% | 47,679 | $0.9000 | $43K | −48,906 | −$95K |
| Phasebio Pharmaceuticals | 0.00% | Hold | 321,856 | $0.0301 | $10K | — | — |
Showing top 50 of 79 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| BHVN - Biohaven | 4.48% | Exit | 0 | $151.17 | $17M | −110,100 | −$17M |
| Aerie Pharmaceuticals | 1.25% | Exit | 0 | $15.13 | $5M | −307,232 | −$5M |
| Mediwound | 0.53% | Exit | 0 | $1.39 | $2M | −1,428,571 | −$2M |
| Ngm Biopharmaceuticals | 0.26% | Exit | 0 | $13.07 | $980K | −74,953 | −$980K |
| Gamida Cell | 0.26% | Exit | 0 | $1.59 | $978K | −614,896 | −$978K |
| Mei Pharma | 0.18% | Exit | 0 | $0.3865 | $683K | −1,767,146 | −$683K |
| Gh Research | 0.16% | Exit | 0 | $11.63 | $612K | −52,631 | −$612K |
| CMPS - Compass Pathways | 0.14% | Exit | 0 | $10.72 | $508K | −47,390 | −$508K |
| PRQR - Proqr Therapeutics | 0.13% | Exit | 0 | $0.7438 | $483K | −649,383 | −$483K |
| Sutro Biopharma | 0.12% | Exit | 0 | $5.55 | $451K | −81,200 | −$451K |
| Otonomy | 0.12% | Exit | 0 | $0.2952 | $434K | −1,470,199 | −$434K |
| Venus Concept | 0.11% | Exit | 0 | $0.4400 | $426K | −968,187 | −$426K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2